Effects Of Rosiglitazone On The Content Of Cholesterol And The Expression Of SR-BI In Foam Cells

Background and Objective Researches showed that the rosiglitazone had the effect of resist to atherosclerosis whether in diabetes or nondiabetes patients. To investigate the effects of rosiglitazone on the content of cholesterol and the expression of acyl-coenzyme A:cholesterol acyltransferase1(ACAT-1) and scavenger class B receptor type I (SR-BI) in RAW264.7macrophage foam cells.Methods RAW264.7macrophage cells were incubated with DMEM medium at37℃,5%CO2, the medium was added penicillin100U/ml, streptromycin100U/ml. The macrophage cells were divided into5groups. The macrophage cells were incubated with DMEM medium for48h; the macrophage cells were add the ox-LDL which final concentration is30mg/L in foam cells group; the macrophage cells were add the rosiglitazone which final concentrations were5μmol/L,10μmol/L,20μmol/L and the ox-LDL which final concentration was30mg/L, they were all incubated for48h. After the cell cultured, Oil Red O staining was used to observe the formation of foam cells. The cholesterol oxidase was employed to determine the content of cellular cholesterol. The Western blot technology was used to observe the expression of the ACAT-1and SR-BI in RAW264.7foam cells.Results Compared with the blank control group, the content of total cholesterol, free cholesterol and cholesterol ester in foam cells groups were increased(P<0.01). Compared with foam cells group, the expression of ACAT-1in rosiglitazone groups (5μmol/L,10μmol/L,20μmol/L)were decreased(P<0.05), which was decreased with concentration; compared with foam cells group, the expression of SR-BI in rosiglitazone groups(5μmol/L,10μmol/L,20μmol/L) were increased(P<0.05), which was increased with concentration.Conclusions Rosiglitazone may decrease the expression of ACAT-1and the expression of SR-BI to decrease the content of cholesterol in foam cells, so as to resistance to atherosclerosis.